A Multicenter, Randomized, Double-Blind, Parallel Group Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Second Generation VIR-7831 Material in Non-Hospitalized Participants With Mild to Moderate Coronavirus Disease 2019 (COVID-19)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sotrovimab (Primary) ; Sotrovimab (Primary)
Indications COVID-19 respiratory infection
Focus Adverse reactions; Pharmacokinetics
Acronyms COMET-PEAK
Sponsors Vir Biotechnology

Most Recent Events

26 Apr 2022 Status changed from active, no longer recruiting to completed.
12 Nov 2021 Results presented in a GlaxoSmithKline media release.
12 Nov 2021 According to a GlaxoSmithKline media release, the companies plan to submit the full COMET-PEAK data set to a peer-reviewed journal for publication.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight